PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW123577View Pathway |
signaling
ahaHomo sapiens
|
Creator: Guest: Anonymous Created On: August 16, 2019 at 01:17 Last Updated: August 16, 2019 at 01:17 |
PW122139View Pathway |
signaling
Agrin in Postsynaptic DifferentiationHomo sapiens
Agrin and acetylcholine act in parallel to shape the postsynaptic apparatus, and skeletal neuromuscular junction development depends critically on the interactions between these factors.
In addition to its role in clustering acetylcholine, which has been demonstrated in vitro, agrin also acts to antagonize the effect of acetylcholine receptors. The antideclustering effects of agrin are physiologically crucial, agrin's antideclustering effects in vitro require its z-exon which has been shown to be required for postsynaptic differentiation in vivo.
|
Creator: Noah Created On: September 12, 2018 at 09:27 Last Updated: September 12, 2018 at 09:27 |
PW128330View Pathway |
drug action
Agomelatine Serotonin Antagonist Action PathwayHomo sapiens
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors and promotes dopamine and norepinephrine release. Agomelatine is indicated to treat major depressive episodes in adults. It is an atypical antidepressant.
|
Creator: Omolola Created On: August 21, 2023 at 16:01 Last Updated: August 21, 2023 at 16:01 |
PW176372View Pathway |
Agomelatine Predicted Metabolism PathwayHomo sapiens
Metabolites of Agomelatine are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 16:25 Last Updated: December 07, 2023 at 16:25 |
PW145720View Pathway |
drug action
Agomelatine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:28 Last Updated: October 07, 2023 at 16:28 |
PW012844View Pathway |
Agnieszka Bielska 1471277183Homo sapiens
|
Creator: Guest: Anonymous Created On: August 15, 2016 at 10:06 Last Updated: August 15, 2016 at 10:06 |
PW002692View Pathway |
signaling
Agnieszka BielskaHomo sapiens
|
Creator: Guest: Anonymous Created On: June 16, 2016 at 06:19 Last Updated: June 16, 2016 at 06:19 |
PW145889View Pathway |
drug action
Afatinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:54 Last Updated: October 07, 2023 at 16:54 |
PW128495View Pathway |
drug action
Afatinib Action PathwayHomo sapiens
Afatinib is a tyrosine kinase inhibitor used as an antineoplastic agent for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. Afatinib binds the phosphorylation domain of the epidermal growth factor receptor. This inhibits the activation of this receptor, thus the cascading signaling pathways, through RAS, can't happen. As a result, this drug provokes the inhibition of cell (cancer) proliferation. Also, Afatinib inhibits the receptor tyrosine-protein kinase erbB-2 and erbB-4. Those receptors usually send a signal to the cell to survive (through the transcription of many proteins and with the help of P13K, AKT, and mTOR). The inhibition of those receptors results in the inhibition of the survival of the cell (death/apoptosis). This drug is administered as an oral tablet.
|
Creator: Daphnee Created On: August 31, 2023 at 15:48 Last Updated: August 31, 2023 at 15:48 |
PW145615View Pathway |
drug action
Afamelanotide Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:13 Last Updated: October 07, 2023 at 16:13 |